Abstract
Hypertension represents the most common cardiovascular risk factor, affecting more than 25% of the adult population in developed societies. Although beta-blockers have been previously shown to effectively reduce blood pressure and have been used for hypertension treatment for over 40 years, their effect on cardiovascular morbidity and mortality in hypertensive patients remains controversial and their use in uncomplicated hypertension is currently still under debate. According to the previous recommendations beta-blockers should not be preferred as first-line therapy in hypertension patients. This review summarizes the current knowledge on application of beta-blockers in patients with hypertension and discusses the most recent guidelines of the European Society of Hypertension (2009) on beta-blockers applications.
Keywords: Hypertension, antihypertensive treatment, beta-blocker, cardiovascular risk, beta-blockers, blood pressure, carteolol, carvedilol, labetalol, nadolol, penbutolol, pindolol, propranolol, timolol, atenolol, betaxolol, bisoprolol, metoprolol, nebivolol, diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, National Institute for Health and Clinical Excellence, ESH/ESC 2007, European Lacidipine Study on Atherosclerosis, Losar-tan Intervention For Endpoint, Anglo-Scandinavian Cardiac Outcomes Trial, Blood Pressure Low-ering Arm, International Verapamil-Trandolapril Study, Metoprolol Atherosclerosis Prevention in Hypertension, ACE inhibitors, Conduit Artery Function Evaluation, Canadian Hypertension Education Program, coronary artery disease CHF, congestive heart failure
Current Vascular Pharmacology
Title: Current Place of Beta-Blockers in the Treatment of Hypertension
Volume: 8 Issue: 6
Author(s): Agata Bielecka-Dabrowa, Wilbert S. Aronow, Jacek Rysz and Maciej Banach
Affiliation:
Keywords: Hypertension, antihypertensive treatment, beta-blocker, cardiovascular risk, beta-blockers, blood pressure, carteolol, carvedilol, labetalol, nadolol, penbutolol, pindolol, propranolol, timolol, atenolol, betaxolol, bisoprolol, metoprolol, nebivolol, diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, National Institute for Health and Clinical Excellence, ESH/ESC 2007, European Lacidipine Study on Atherosclerosis, Losar-tan Intervention For Endpoint, Anglo-Scandinavian Cardiac Outcomes Trial, Blood Pressure Low-ering Arm, International Verapamil-Trandolapril Study, Metoprolol Atherosclerosis Prevention in Hypertension, ACE inhibitors, Conduit Artery Function Evaluation, Canadian Hypertension Education Program, coronary artery disease CHF, congestive heart failure
Abstract: Hypertension represents the most common cardiovascular risk factor, affecting more than 25% of the adult population in developed societies. Although beta-blockers have been previously shown to effectively reduce blood pressure and have been used for hypertension treatment for over 40 years, their effect on cardiovascular morbidity and mortality in hypertensive patients remains controversial and their use in uncomplicated hypertension is currently still under debate. According to the previous recommendations beta-blockers should not be preferred as first-line therapy in hypertension patients. This review summarizes the current knowledge on application of beta-blockers in patients with hypertension and discusses the most recent guidelines of the European Society of Hypertension (2009) on beta-blockers applications.
Export Options
About this article
Cite this article as:
Bielecka-Dabrowa Agata, S. Aronow Wilbert, Rysz Jacek and Banach Maciej, Current Place of Beta-Blockers in the Treatment of Hypertension, Current Vascular Pharmacology 2010; 8 (6) . https://dx.doi.org/10.2174/157016110793563861
DOI https://dx.doi.org/10.2174/157016110793563861 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Amniotic Fluid Embolism: Review
Current Pharmaceutical Biotechnology Effects of Peroxyl Radicals on Contractility of Rabbit Aorta and Guinea Pig Atria
Endocrine, Metabolic & Immune Disorders - Drug Targets Conformation and Bioactivity. Design and Discovery of Novel Antihypertensive Drugs
Current Topics in Medicinal Chemistry Secondary Hypertension: Novel Insights
Current Hypertension Reviews Association between Apo B Levels in Mothers and in their Pre-school Age Offspring
Cardiovascular & Hematological Agents in Medicinal Chemistry Atrial Macroreentry in Congenital Heart Disease
Current Cardiology Reviews Hypertension and Diabetes: Emphasis on the Renin – Angiotensin System and Insulin Resistance
Current Hypertension Reviews Expression and Role of the Calcium-Sensing Receptor in the Blood Vessel Wall
Current Pharmaceutical Biotechnology Modifying Anti-Inflammatory Effect of Diclofenac with Murraya koenigii
Recent Patents on Inflammation & Allergy Drug Discovery Regenerative Therapies for Improving Myocardial Perfusion in Patients with Cardiovascular Disease: Failure to Meet Expectations but Optimism for the Future
Current Vascular Pharmacology Mutation p.S335X in GATA4 Reduces its DNA Binding Affinity and Enhances Cell Apoptosis Associated with Ventricular Septal Defect
Current Molecular Medicine cGMP Signaling, Phosphodiesterases and Major Depressive Disorder
Current Neuropharmacology Rationale of Statin Therapy in Septic Patients
Current Vascular Pharmacology Functional Effects of Levosimendan in Rat Basilar Arteries In Vitro
Current Neurovascular Research The Clinical Trials of Mesenchymal Stem Cell Therapy in Skin Diseases: An Update and Concise Review
Current Stem Cell Research & Therapy Identification of Candidate Biomarkers of Acute Aortic Dissection
Recent Patents on DNA & Gene Sequences The Temporal Relationship between Pain Intensity and Pain Interference and Incident Dementia
Current Alzheimer Research Recent Developments in the Field of Quinazoline Chemistry
Current Organic Chemistry Systemic Sclerosis: Clinical Manifestations
Current Rheumatology Reviews Urotensin-II Receptor: A Double Identity Receptor Involved in Vasoconstriction and in the Development of Digestive Tract Cancers and other Tumors
Current Cancer Drug Targets